rp2
Biologicalexperimental
Clinical trial activity
6 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
4
Phase 3
1
Phase 4
0
Earliest trial started Oct 17, 2019 (NCT04336241)
Timeline
Indications
Mechanism of action
- Oncolytic virusOTHER
Oncolytic virus other
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07218692 | Phase 2 | Aug 11, 2026 | City of Hope National Medical Center, National Cancer Institute (NCI) |
| NCT07059611 | Phase 2 | Nov 8, 2025 | Replimune Inc., University of Pennsylvania |
| NCT06623110 | Phase 2 | Mar 31, 2025 | Harvard University, Replimune Inc. |
| NCT06581406 | Phase 2/Phase 3 (Phase 3) | Jan 27, 2025 | Replimune Inc. |
| NCT05733611 | Phase 2 | Jun 29, 2023 | Replimune Inc., Roche |
| NCT04336241 | Phase 1 | Oct 17, 2019 | Replimune Inc. |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Replimune Inc. | For profit | 5 | 3 | 3 | 2019 |
| City of Hope National Medical Center | Academic/Hospital | 1 | 1 | 1 | 2026 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2026 |
| Roche | For profit | 1 | 0 | 1 | 2023 |
| University of Pennsylvania | Academic/Hospital | 1 | 1 | 1 | 2025 |
6 organizations
Page 1 / 1